Oruka Therapeutics, Inc.'s latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 6 Aug 2026Directors make major company decisions; voters approved new board members to lead until 2029.
Company can now develop ORKA-001 for a new disease, potentially opening a bigger market opportunity.
Quarterly updates show company health and cash runway, helping investors track financial progress.
Strong cash position funds drug development; new stock sale raises 658 million more for operations.
Company gets cash to fund drug trials and operations; your ownership stake gets diluted if you own shares.
Preliminary announcement of share sale to fund the company; final details coming soon.
First draft of offering details released; allows investors to review terms before final sale.
Stocky reads Oruka Therapeutics, Inc.'s official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
Oruka Therapeutics, Inc.'s most recent tracked filing was a 8-K on 4 Jun 2026: Stockholders elect directors Lawrence Klein and Chris Martin.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 6 Aug 2026.